Experimental hepatitis b drug trial halted early
NCT ID NCT02452528
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental drug called ARC-520 in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if ARC-520 could further lower hepatitis B surface antigen levels. Only 4 people enrolled before the study was stopped, so we have very little information about how well it works or its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARC-520
What this could lead to
If successful, this could point toward a more effective way to control chronic hepatitis B by reducing viral markers.
What could go wrong
This early-phase trial was terminated with only 4 participants, so results are very limited. The drug may not work or could have safety issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
San Francisco, California, 94118, United States
-
Research Site 2
Miami, Florida, 33136, United States
-
Research Site 4
New York, New York, 10029, United States
-
Research Site 6
San Antonio, Texas, 78215, United States